Results 131 to 140 of about 48,011 (239)

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Impact of HLA antigen and antibody expression on cross-matching and transfusion effect

Zhongguo shuxue zazhi
[Objective] To study the relationship between the expression intensity of HLA-Ⅰ platelet antibodies in patients with platelet transfusion refractoriness (PTR) and platelet cross-matching, and to further evaluate other factors in order to provide relevant
HE Honghong, CHENG Jing, WANG Yihan, JIANG Min, TANG Longhai   +4 more
doaj   +1 more source

Comparative evaluation of blood component preparation with the top‐and‐top and top‐and‐bottom methods: A change in Uruguay

Transfusion Medicine, Volume 36, Issue 3, Page 260-264, June 2026.
Abstract Background Hospital de Clínicas, in conjunction with the Universidad de la República UDELAR in Uruguay, evaluated the quality of blood components after separation with a top‐and‐bottom (TB) system, comparing it with the top‐and‐top (TT) system and verifying compliance with local and international standards. Study Design and Methods Whole blood
Natalia Méndez Acosta, Gabriela Rivas Alén, Ismael Rodriguez Grecco, Allexandra Díaz, Dalia Moreno, Ludwig R. Frontier Ramos   +5 more
wiley   +1 more source

Anti-HLA antibody formation increases the chances of platelet refractoriness in platelet-transfused patients: a systematic review with meta-analysis

Hematology, Transfusion and Cell Therapy
Platelet refractoriness caused by alloimmunization to anti-HLA antibodies remains present in daily hemotherapy: the frequent need for platelet transfusions may influence the long-term survival of treated patients. This study aimed to perform a systematic
Luana Joana Barreto Cabral, D. Lopes, Eduardo dos Santos Martins Filho, R. Valois, Paula Christine Amarantes Justino Oliveira, Patrícia Jeanne de Souza Mendonça-Mattos   +5 more
semanticscholar   +1 more source

Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions

The Turkish Journal of Pediatrics, 2003
Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte ...
Omer Devecioğlu, Ayşegül Unüvar, Sema Anak, Ilmay Bilge, Haluk Ander, Orhan Ziylan   +5 more
doaj  

Prediction model of platelet transfusion refractoriness in patients with hematological disorders

Zhongguo shuxue zazhi
Objective To explore the risk factors for platelet transfusion refractoriness(PTR)in patients with hematological disorders, construct a prediction model and validate the model efficacy.
Shuhan YUE, Xiulan HUANG, Yan ZENG, Qiao LEI, Mengzhen HE, Liqi LU, Shisong YOU, Jingwei ZHANG   +7 more
doaj   +1 more source

Prevalence of specific antibodies and genotypes of Human Leukocyte Antigens (HLA) and Human Platelet Antigens (HPA) causing immunological refractoriness to platelet transfusion in oncohematological patients at the san ignacio university hospital.

, 2023
La transfusión de plaquetas profiláctica y terapéutica es una práctica común en pacientes hospitalizados; sin embargo, los pacientes pueden experimentar refractariedad a la transfusión de plaquetas, un fenómeno en el que no se logra el incremento ...
Sierra Arenas, Yenit Katherine
core  

[Incidence and clinical significance of platelet transfusion refractoriness after allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia]. [PDF]

Zhonghua Xue Ye Xue Za Zhi, 2022
Zhao C, Zhao XS, Wang Y, Yan CH, Xu LP, Zhang XH, Liu KY, Huang XJ, Sun YQ.   +8 more
europepmc   +1 more source

[Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness.]

, 2014
International audiencePlatelet refractoriness is a serious complication for patients receiving recurrent platelet transfusions, which can be explained by non-immune and immune causes.
Basire, A, Picard, Christophe
core  

Factors influencing platelet count increment after platelet transfusion among thrombocytopenic patients in Hospital USM [PDF]

, 2016
Many studies had been performed to determine the factors that may contribute to posttransfusion platelet increment. However, no documented data is available in our institution in this area of knowledge yet.
Hayat, Mohd Zamri Mohd
core